- Home
- CHRS vs ACTU Comparison
CHRS vs ACTU Comparison
Compare CHRS & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ACTU
- Stock Information
- Founded
- CHRS 2010
- ACTU 2015
- Country
- CHRS United States
- ACTU United States
- Employees
- CHRS N/A
- ACTU N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ACTU
- Sector
- CHRS Health Care
- ACTU
- Exchange
- CHRS Nasdaq
- ACTU NYSE
- Market Cap
- CHRS 112.5M
- ACTU 135.0M
- IPO Year
- CHRS 2014
- ACTU 2024
- Fundamental
- Price
- CHRS $0.76
- ACTU $8.65
- Analyst Decision
- CHRS Buy
- ACTU Strong Buy
- Analyst Count
- CHRS 3
- ACTU 1
- Target Price
- CHRS $4.68
- ACTU $20.00
- AVG Volume (30 Days)
- CHRS 1.2M
- ACTU 69.7K
- Earning Date
- CHRS 08-07-2025
- ACTU 05-15-2025
- Dividend Yield
- CHRS N/A
- ACTU N/A
- EPS Growth
- CHRS N/A
- ACTU N/A
- EPS
- CHRS N/A
- ACTU N/A
- Revenue
- CHRS $272,251,000.00
- ACTU N/A
- Revenue This Year
- CHRS N/A
- ACTU N/A
- Revenue Next Year
- CHRS $132.69
- ACTU N/A
- P/E Ratio
- CHRS $1.79
- ACTU N/A
- Revenue Growth
- CHRS 19.87
- ACTU N/A
- 52 Week Low
- CHRS $0.66
- ACTU $5.51
- 52 Week High
- CHRS $2.43
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- CHRS 40.42
- ACTU N/A
- Support Level
- CHRS $0.74
- ACTU N/A
- Resistance Level
- CHRS $0.90
- ACTU N/A
- Average True Range (ATR)
- CHRS 0.05
- ACTU 0.00
- MACD
- CHRS 0.01
- ACTU 0.00
- Stochastic Oscillator
- CHRS 13.56
- ACTU 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.